探讨 G 蛋白偶联受体30 (GPR30 )在宫颈病变及宫颈癌发生中的作用

摘要

Objective:Explore the estrogen receptor GPR30 in the expression and significance of cervical cancer and precancerous le-sions . Methods:Using immunohistochemical SP method to detect GPR30 in normal cervical tissue and CIN and cervical cancer tissues , The expression and clinical pathological analysis of GPR30 contact;Preliminary discussion on the role of GPR30 in cervical lesions and cervical cancer before and its mechanism. Results:In normal cervical tissue,cervical intraepithelial neoplasia and cervical cancer,the positive expression rates of GPR30 were:23. 3%、53. 3%、81. 2%. The cervical carcinoma GPR30 positive expression rate is highest, higher than that of the CIN group and normal group,the difference was significant (χ2 =4. 403,P=0. 036;χ2 =19. 288,P=0. 001). The difference between the normal and the CIN group was statistical significant (χ2 =13. 125,P=0. 001).%目的:探讨G蛋白偶联受体30 (GPR30)在宫颈癌及癌前病变的表达及意义.方法:用免疫组化法检测GPR30在正常宫颈组织、CIN和宫颈癌组织中的表达,分析GPR30表达与临床病理的联系;初步探讨GPR30在宫颈癌前病变及宫颈癌中的作用及其机制.结果:正常组、CIN 组及宫颈癌组中,GPR30 阳性表达率分别为23. 3%、53. 3%、81. 2%,其中宫颈癌GPR30阳性表达率最高,分别高于高级别CIN 组及正常组,差异有统计学意义 (χ2 =4. 403,P=0. 036;χ2 =19. 288,P=0. 001);高级别CIN组GPR30阳性表达率高于正常组,差异有统计学意义 (χ2 =13. 125,P=0. 001).